Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Operating Leases (2020 - 2025)

Immucell (ICCC) has disclosed Operating Leases for 6 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 0.8% year-over-year to $4.1 million, compared with a TTM value of $4.1 million through Sep 2025, down 0.8%, and an annual FY2024 reading of $4.6 million, up 11.87% over the prior year.
  • Operating Leases was $4.1 million for Q3 2025 at Immucell, down from $4.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.7 million in Q1 2024 and bottomed at $159396.0 in Q4 2021.
  • Average Operating Leases over 5 years is $2.9 million, with a median of $4.0 million recorded in 2024.
  • The sharpest move saw Operating Leases crashed 85.96% in 2021, then surged 1291.14% in 2022.
  • Year by year, Operating Leases stood at $159396.0 in 2021, then soared by 1291.14% to $2.2 million in 2022, then soared by 83.87% to $4.1 million in 2023, then increased by 11.87% to $4.6 million in 2024, then decreased by 9.78% to $4.1 million in 2025.
  • Business Quant data shows Operating Leases for ICCC at $4.1 million in Q3 2025, $4.1 million in Q2 2025, and $4.1 million in Q1 2025.